RY 160.0 1.8784% SHOP 136.33 4.2916% TD 84.63 1.6332% ENB 61.52 0.1628% BN 72.41 3.1775% TRI 247.36 0.7987% CNQ 42.21 1.9812% CP 108.09 2.8645% CNR 140.3 1.3143% BMO 139.17 1.5691% BNS 68.87 1.012% CSU 4698.7998 1.5169% CM 80.73 1.5344% MFC 42.33 3.2439% ATD 67.77 -0.5576% NGT 66.45 0.7734% TRP 67.71 0.6092% SU 52.65 1.7981% WCN 266.11 0.6658% L 187.43 1.1167%
Last update at 2025-03-16T23:40:00Z
Telix Adds Lead-212 Isotope Production Capability
Wed 12 Mar 25, 10:48 PMInvestor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
Mon 03 Mar 25, 09:58 PMFDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
Wed 26 Feb 25, 12:49 AMTelix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
Mon 24 Feb 25, 05:00 PMIlluccix® Approved in the United Kingdom
Wed 12 Feb 25, 09:38 PMIs Telix Pharmaceuticals Limited (TLX) the Best Long Term ASX Stock to Buy Now?
Tue 11 Feb 25, 04:47 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -98.62200M | -80.46500M | -47.93500M | -31.12200M | -15.71389M |
| Minority interest | - | - | - | - | - |
| Net income | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.82982M |
| Selling general administrative | 77.32M | 34.92M | 18.01M | 11.28M | 8.50M |
| Selling and marketing expenses | 16.19M | 5.89M | 1.20M | 0.31M | 0.58M |
| Gross profit | 94.43M | 2.35M | 2.66M | 0.94M | 0.20M |
| Reconciled depreciation | 5.38M | 5.17M | 4.88M | 4.24M | 0.00697M |
| Ebit | -92.20600M | -75.24700M | -46.76000M | -28.71400M | -15.68487M |
| Ebitda | -86.82700M | -70.07300M | -41.87800M | -24.47800M | -15.67791M |
| Depreciation and amortization | 5.38M | 5.17M | 4.88M | 4.24M | 0.00697M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -92.20600M | -75.24700M | -46.76000M | -28.71400M | -27.65396M |
| Other operating expenses | 251.00M | 103.70M | 54.47M | 43.74M | - |
| Interest expense | 6.42M | 5.22M | 1.18M | 2.41M | 0.03M |
| Tax provision | 5.46M | 0.04M | -3.04800M | -3.25500M | -1.88407M |
| Interest income | 0.00100M | 0.16M | 0.07M | 2.39M | 1.80M |
| Net interest income | -6.69200M | -5.21800M | -1.10800M | -2.31000M | 0.30M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 5.46M | 0.04M | -3.04800M | -3.25500M | -1.88407M |
| Total revenue | 155.98M | 4.90M | 4.68M | 3.48M | 0.20M |
| Total operating expenses | 189.44M | 101.15M | 52.44M | 41.20M | 27.85M |
| Cost of revenue | 61.56M | 2.55M | 2.02M | 2.54M | 0.00000M |
| Total other income expense net | -6.41600M | -5.21800M | -1.17500M | -2.40800M | 11.94M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.82982M |
| Net income applicable to common shares | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.83000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 1516.43M | 398.30M | 255.35M | 109.81M | 157.82M |
| Intangible assets | 309.49M | 104.82M | 53.47M | 51.63M | 54.97M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 7.10M | 6.57M | 1.43M | 1.79M |
| Total liab | 948.22M | 249.39M | 175.35M | 107.66M | 78.81M |
| Total stockholder equity | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 85.91M | 123.01M | 68.11M | 6.14M | 6.29M |
| Common stock | - | 446.27M | 370.97M | 170.84M | 167.06M |
| Capital stock | 0.00000M | 446.27M | 370.97M | 170.84M | 167.06M |
| Retained earnings | -212.96200M | -263.66500M | -272.81500M | -173.47100M | -92.96100M |
| Other liab | - | - | 79.98M | 67.77M | 57.41M |
| Good will | 106.65M | 4.85M | 5.52M | 4.10M | 4.22M |
| Other assets | - | - | 3.97M | 0.21M | 0.18M |
| Cash | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 330.91M | 157.41M | 85.56M | 37.98M | 19.96M |
| Current deferred revenue | - | 112.02M | - | 19.32M | 7.09M |
| Net debt | - | -105.79200M | -105.88300M | -19.49800M | -75.73800M |
| Short term debt | - | 1.56M | 0.64M | 0.63M | 0.77M |
| Short long term debt | 18.99M | 0.96M | - | 0.02M | 0.26M |
| Short long term debt total | - | 17.45M | 10.45M | 2.54M | 2.21M |
| Other stockholder equity | - | - | -0.56200M | 4.79M | 4.92M |
| Property plant equipment | - | - | 18.84M | 6.33M | 4.82M |
| Total current assets | 918.56M | 224.85M | 173.23M | 47.54M | 93.63M |
| Long term investments | 6.09M | 12.26M | - | - | - |
| Net tangible assets | - | - | 21.02M | -53.57100M | 19.83M |
| Short term investments | - | - | - | - | - |
| Net receivables | 139.44M | 64.78M | 39.35M | 19.42M | 12.40M |
| Long term debt | 551.82M | 8.21M | 3.31M | 0.00000M | 0.10M |
| Inventory | 38.14M | 17.31M | 8.48M | 3.45M | 0.63M |
| Accounts payable | 68.70M | 32.84M | 16.81M | 11.88M | 5.81M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -33.69200M | -18.15000M | 4.79M | 4.92M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 167.06M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 74.58M | 1.17M | 0.33M | 0.21M | 0.18M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 597.87M | 173.45M | 82.12M | 62.27M | 64.19M |
| Capital lease obligations | 10.64M | 8.27M | 7.13M | 2.52M | 1.85M |
| Long term debt total | - | - | 9.80M | 1.91M | 1.44M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -135.17300M | -25.48900M | -16.99700M | -2.72600M | -1.09100M |
| Change to liabilities | - | - | 27.64M | 4.79M | 32.42M |
| Total cashflows from investing activities | - | - | -16.99700M | -2.72600M | -1.09100M |
| Net borrowings | - | - | 1.74M | -0.93600M | -0.90400M |
| Total cash from financing activities | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M |
| Change to operating activities | - | - | -3.68600M | 2.60M | -0.19300M |
| Net income | 49.92M | 5.21M | -104.07900M | -80.51000M | -44.88700M |
| Change in cash | 587.11M | 6.91M | 94.29M | -55.90800M | 33.35M |
| Begin period cash flow | 123.24M | 116.33M | 22.04M | 77.94M | 44.60M |
| End period cash flow | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
| Total cash from operating activities | - | 23.88M | -63.97000M | -59.32800M | 1.96M |
| Issuance of capital stock | 1.00M | 6.65M | 181.04M | 3.78M | 35.15M |
| Depreciation | - | 6.92M | 5.38M | 5.17M | 4.88M |
| Other cashflows from investing activities | -34.16900M | -1.17100M | -2.16300M | -1.38700M | -0.44700M |
| Dividends paid | - | - | 168.41M | - | 34.49M |
| Change to inventory | - | -9.63600M | -5.02300M | -2.82100M | -0.09100M |
| Change to account receivables | - | -27.38200M | -19.93400M | -7.19200M | -0.32800M |
| Sale purchase of stock | - | - | -7.81600M | 3.78M | -0.13000M |
| Other cashflows from financing activities | -14.88400M | -2.22200M | -1.26400M | -0.59600M | -0.50200M |
| Change to netincome | - | - | 35.74M | 18.64M | 10.15M |
| Capital expenditures | 34.03M | 10.79M | 13.86M | 1.34M | 0.32M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | - | -57.53400M | -1.00700M | -2.63000M | 31.81M |
| Stock based compensation | - | 8.79M | 8.11M | 1.32M | 2.35M |
| Other non cash items | - | 60.50M | 41.00M | 31.52M | 18.66M |
| Free cash flow | 9.00M | 13.09M | -77.83100M | -60.66700M | 1.64M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLX Telix Pharmaceuticals Ltd |
0.66 2.40% | 27.89 | 180.00 | 59.52 | 11.54 | 15.90 | 11.37 | 96.22 |
| CSL CSL Ltd |
-0.28 0.11% | 249.77 | 28.80 | 34.48 | 7.96 | 4.10 | 5.89 | 18.29 |
| MSB Mesoblast Ltd |
- -% | 2.07 | - | 454.55 | 464.76 | 3.53 | 302.48 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
0.35 3.00% | 12.03 | 10.28 | 65.36 | 6.68 | 3.94 | 5.69 | 6.91 |
| CU6 Clarity Pharmaceuticals Ltd |
-0.03 1.14% | 2.60 | - | - | 78.13 | 6.59 | -0.7791 |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
55 Flemington Road, North Melbourne, VIC, Australia, 3051
| Name | Title | Year Born |
|---|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, Group MD, CEO & Exec. Director | 1975 |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Director | NA |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 1965 |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist | NA |
| Ms. Kyahn Williamson | Sr. VP of Corp. Communications & Investor Relations | NA |
| Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. | Sr. VP of Global Governance, Risk & Compliance | NA |
| Ms. Lena Moran-Adams | Gen. Counsel | NA |
| Ms. Amanda Griffin | Communications Mang. | NA |
| Mr. Christian Davis | VP Sales and Marketing, EMEA | NA |
| Ms. Meredith Crowe | Interim Sr. VP of Global People & Culture | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...